GSK plc (GSK)

NYSE: GSK · IEX Real-Time Price · USD
40.31
-0.26 (-0.64%)
At close: Aug 8, 2022 4:00 PM
40.49
+0.18 (0.45%)
After-hours: Aug 8, 2022 5:21 PM EDT
-0.64%
Market Cap 81.98B
Revenue (ttm) 43.06B
Net Income (ttm) 5.56B
Shares Out 2.03B
EPS (ttm) 2.76
PE Ratio 14.61
Forward PE 11.89
Dividend $1.98 (4.91%)
Ex-Dividend Date Aug 18, 2022
Volume 2,889,524
Open 40.56
Previous Close 40.57
Day's Range 40.18 - 40.66
52-Week Range 32.96 - 47.89
Beta 0.18
Analysts Buy
Price Target 53.20 (+32.0%)
Earnings Date Jul 27, 2022

About GSK

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, ... [Read more...]

Industry Pharmaceuticals
Founded 1715
CEO Emma Walmsley
Employees 90,096
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2021, GSK plc's revenue was 34.11 billion, an increase of 0.04% compared to the previous year's 34.10 billion. Earnings were 4.39 billion, a decrease of -23.73%.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 34 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 53.2, which is an increase of 31.98% from the latest price.

Price Target
$53.2
(31.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in comm...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leade...

GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leade...

GSK or Haleon: Which Is the Real Beneficiary of This Spinoff?

GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.

Other symbols: HLN

Could GSK's Haleon Spinoff Backfire?

GSK PLC ( GSK , Financial) completed the long-awaited spinoff of its consumer health care business Haleon ( HLN , Financial) on July 18. Shareholders received one Haleon share for each GSK share owned.

Other symbols: HLN

GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.

GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active l...

Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell

Early Wednesday, GSK stock dipped slightly despite beating second-quarter expectations and raising its full-year guidance. The post Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell appe...

7 Dividend Stocks to Buy on the Dip

With the stock market still volatile and in a bottoming process, it's a good time to find dividend stocks to buy on the dip. As the old saying goes, dividend stocks “pay you to wait.

Other symbols: BBYBEPBXDJPMMCD

GSK lifts full-year forecast, days after consumer health spinoff

GSK on Wednesday lifted its full-year forecast, boosted by reinvigorated demand for its blockbuster Shingrix vaccine, days after overhauling the business with the spinoff of its consumer health unit.

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Other symbols: ALKSBIIBBMYTEVA

Why GlaxoSmithKline Stock Jumped 25% on Thursday

Investors may be warming to the company's spin-off of its consumer healthcare division.

3 Biotech Stocks to Buy on the Dip

Biotech stocks have rebounded lately and are poised to keep surging, so it's a good time to buy biotech stocks on the dip. The post 3 Biotech Stocks to Buy on the Dip appeared first on InvestorPlace.

Other symbols: SDGR

We expected volatility in the early days of trading, says Haleon CEO Brian McNamara

Brian McNamara, Haleon CEO, joins 'Squawk Box' to discuss the company first few days as a publicly traded company.

GSK Completes Demerger of Consumer Healthcare Business

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

Haleon launches with purpose to deliver better everyday health with humanity

Maker of Sensodyne, Advil, and TUMS becomes one of the world's leading independent consumer health companies Demerger from GSK plc (GSK) now complete WARREN, N.J. , July 18, 2022 /PRNewswire/ -- Today, ...

GSK spinoff starts trading at LSE – what you need to know

Monday, July 18, is set up to be a big day for GlaxoSmithKline (NYSE: GSK) and the London Stock Exchange.

GSK spinoff Haleon starts trading in largest European listing in a decade

Europe's biggest listing in a decade, Haleon, started trading on the London Stock Exchange on Monday. Haleon in the consumer-health business spinoff of GSK GSK, -19.57%.

After bruising year, GSK approaches consumer split in better health

Things are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to spin off its consumer health business on Monday in London's biggest listing in a decade and the company's...

GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses

PHILADELPHIA--(BUSINESS WIRE)-- #Flu--GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses

How Its New Vaccine Could Propel GSK's Growth

GSK leads the race to deliver a vaccine for an untreated infectious disease.

How to Earn $10,000 a Year in Passive Retirement Income

You'll either need a decent chunk of change or some patience.

Other symbols: ABBVGILD

7 Retirement Stocks to Buy in July

Planning for retirement can feel overwhelming in bear markets, but these seven retirement stocks can provide a boost to savings. Caterpillar (CAT): The heavy equipment manufacturer is enjoying strong de...

Other symbols: CATENBJNJORCLSTZSTT

GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

PHILADELPHIA--(BUSINESS WIRE)-- #Diversity--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community

Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron

Sanofi SNY, +0.38% SAN, +3.70% and GlaxoSmithKline GSK, +1.86% said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data...

Other symbols: SNY

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.  "Sanofi-GSK's vaccine is the firs...

Other symbols: SNY